Clinical Trial Update: Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of crizotinib completed in invasive lobular breast cancer, gastric cancer, and triple-negative breast cancer populations; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Invasive Lobular Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Lobular Breast Carcinoma, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-10-30